Drug
MAP0004
MAP0004 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
100%(5 trials)
Phase Distribution
Ph phase_1
4
80%
Ph phase_3
1
20%
Phase Distribution
4
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 14 (80.0%)
Phase 31 (20.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole
NCT01468558
completedphase_1
Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers
NCT01199965
completedphase_3
Phase 3 Study of MAP0004 in Adult Migraineurs
NCT00623636
completedphase_1
Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
NCT01089062
completedphase_1
QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo
NCT01191723
Clinical Trials (5)
Showing 5 of 5 trials
NCT01468558Phase 1
Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole
NCT01199965Phase 1
Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers
NCT00623636Phase 3
Phase 3 Study of MAP0004 in Adult Migraineurs
NCT01089062Phase 1
Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
NCT01191723Phase 1
QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5